Join our daily newsletter At The Bell to receive exclusive market insights
- Biotech company Immutep (IMM) receives a patent from the Japanese Patent Office for LAG525
- The patent is titled “antibody molecules to LAG-3 and uses thereof” and will expire on March 13, 2035
- LAG525 is a humanised form of Immutep’s IMP701 antibody that was developed to target LAG-3 – cell surface molecules with diverse biologic effects on T cell function
- It activates T cells by obstructing inhibitory signals that would otherwise switch them off and prevent them from locating foreign object
- Immutep ends the day in the green with shares trading at 39.5 cents
Biotech company Immutep (IMM) has received a patent from the Japanese Patent Office for LAG525.
The patent is titled “antibody molecules to LAG-3 and uses thereof” and will expire on March 13, 2035.
The patent was filed as a divisional application and follows the grant of the parent Japanese patent announced in 2019.
Similar patents have been granted in other countries such as Australia, Europe, China and the United States.
LAG525 is a humanised form of Immutep’s IMP701 antibody that was developed to target LAG-3 (Lymphocyte Activation Gene-3) – cell surface molecules with diverse biologic effects on T cell function.
It works by blocking T cells, part of the immune system that focuses on specific foreign particles, by obstructing inhibitory signals that would otherwise switch them off and prevent them from locating foreign objects.
Therefore, IMP701 removes two brakes that prevent the immune system from killing the cancer cells.
LAG525 is currently being evaluated in phase I and II clinical trials for the treatment of cancer.
Immutep has ended the day 6.76 per cent in the green with shares trading at 39.5 cents.
